12:00 AM
 | 
Apr 19, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Copaxone glatiramer acetate: Post-marketing study data

Data from a 12-month, open-label, post-marketing study in 1,216 MS patients on interferon beta showed that availability of testing for neutralizing antibodies (nAbs) led to significantly more changes in treatment (p<0.0069). Patients who received regular testing for nAbs were significantly more likely to start a treatment of corticosteroids (p=0.0022) or...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >